Reading JNJ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JNJ free→Reading JNJ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track JNJ free→QuarterlyIQ Insights · JNJ
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of operations and financial condition On April 14, 2026, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 29, 2026.
Other Events On April 14, 2026, Johnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the cl…
Results of operations and financial condition On January 21, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025.
Results of operations and financial condition On October 14, 2025, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 28, 2025.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual. Mr. Morikis will serve on the Audit Committee and Compensation & Benefits Committee. As a non-employee…
Results of operations and financial condition On July 16, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 29, 2025.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On June 10, 2025, Johnson & Johnson (the “Company” or “Johnson & Johnson”) announced that Daniel Pinto was elected to the Board of Directors effective July 1, 2025. Mr. Pinto will serve on the Audit Committee and the Compensation & Benefits Committee. As a non-employee director of the Company, Mr. Pinto will receive compensation as described in the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23 rd that he will join Goldman Sachs as a Partner. The retirement will be effective May 31, 2025. His retirement is for personal reasons and not as a result of any disagreement with management on any matter r…
Results of operations and financial condition On April 15, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 30, 2025.
Other Events On April 15, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the c…
Results of operations and financial condition On January 22, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 29, 2024.
Results of operations and financial condition On October 15, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 29, 2024.
Regulation FD Disclosure On September 20, 2024, the Company announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankruptcy case today in the in U.S. Bankruptcy Court for the Southern District of Texas Houston Division to fully and finally resolve of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against the Company and its affiliates in the United States. Red River filed the bankruptcy case af…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2024, D. S. Davis retired as a Director of Johnson & Johnson after the successful transition of Audit Committee Chair responsibilities to D. Adamczyk. His retirement is for personal reasons and not as a result of any disagreement with management on any matter relating to the Company ’ s operations, policies, or practices.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 26, 2024, Johnson & Johnson (the Company) issued a press release announcing that Peter M. Fasolo, Executive Vice President, Chief Human Resources Officer (CHRO), has elected to retire. He will step down from the role of CHRO and member of the Executive Committee, effective October 1, 2024, and depart the Company at the end of the year. A…
Results of operations and financial condition On July 17, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 30, 2024.
Regulation FD Disclosure On May 1, 2024, the Company announced a proposed Plan of Reorganization (the “Proposed Plan”) for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approx…
Results of Operations and Financial Condition On May 1, 2024, Johnson & Johnson issued the attached earnings schedules for the first quarter ended March 31, 2024. These schedules have been amended to reflect the information referenced in
Other Events On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 4.2% increase in the quarterly dividend rate, from $1.19 to $1.24 per share, marking the 62nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend is payable on June 4, 2024 to shareholders of record as of the clos…
Results of Operations and Financial Condition On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 31, 2024.
Results of Operations and Financial Condition On January 23, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 31, 2023.
Other Events Today, the Company announced its acquisition of Laminar, Inc. As a result of the acquisition, Johnson & Johnson will be adjusting its expected Adjusted Fiscal Year 2023 EPS. The asset acquisition will require an in-process research and development charge which will reduce operational and reported Adjusted EPS by approximately $0.17 from guidance previously issued. The new expected operational and reported Adjusted EPS ranges are now $9.85 to $9.91 and $9.90 to $9.96, respectively…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 21, 2023, the Compensation & Benefits Committee (the “Committee”) of the Board of Directors of Johnson & Johnson (the “Company”) approved the adoption of the Johnson & Johnson Deferred Compensation Plan (the “Plan”). The Plan is an unfunded, nonqualified deferred compensation plan that provides eligible management and other highly-compe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 23, 2023, the Company announced that Ashley McEvoy resigned from her position as Executive Vice President, Worldwide Chair MedTech and member of the Executive Committee effective October 20, 2023, and will depart the Company in the first quarter of 2024 after a transition period. The Company’s related press release is attached to this Rep…
Results of Operations and Financial Condition On October 17, 2023, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended October 1, 2023.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.